Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-α 2b treatment

BACKGROUND: High-dose interferon-alpha 2b (IFN-α 2b) is the only approved systemic therapy in the United States for the adjuvant treatment of melanoma. The study objective was to explore the immunomodulatory mechanism of action for IFN-α 2b by measuring serum regulatory T cell (Treg), serum transfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Ascierto, Paolo A, Napolitano, Maria, Celentano, Egidio, Simeone, Ester, Gentilcore, Giusy, Daponte, Antonio, Capone, Mariaelena, Caracò, Corrado, Calemma, Rosa, Beneduce, Gerardo, Cerrone, Margherita, De Rosa, Vincenzo, Palmieri, Giuseppe, Castello, Giuseppe, Kirkwood, John M, Marincola, Francesco M, Mozzillo, Nicola
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936304/
https://www.ncbi.nlm.nih.gov/pubmed/20712892
http://dx.doi.org/10.1186/1479-5876-8-76

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936304/
https://www.ncbi.nlm.nih.gov/pubmed/20712892
http://dx.doi.org/10.1186/1479-5876-8-76

Ejemplares similares